TriangleNCT00087698 · OUTCOME
Time to Progressive Disease
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- months
- Interval / dispersion
- Full Range
- Time frame
- baseline to measured progressive disease
What was measured
Number of months between the first dose date and the date of first disease progression or death as a result of any cause, whichever comes first.
Analysis population: All participants who had undergone surgery.
Groups in this outcome
Pemetrexed
pemetrexed: 500 mg/m2, intravenous, every 21 days x 4 cycles cisplatin: 75 mg/m2, intravenous, every 21 days x 4 cycles chemotherapy, surgery then chest radiation x 54 gray (Gy)
| Group | Source count |
|---|---|
| Pemetrexed | 57 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Pemetrexed | 14.98 | Not reported | 2.56 | 46.00 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 2.56
- upper Limit
- 46.00
- value
- 14.98
- denoms
- counts
- group Id
- OG000
- value
- 57
- units
- Participants
- description
- Number of months between the first dose date and the date of first disease progression or death as a result of any cause, whichever comes first.
- dispersion Type
- Full Range
- groups
- description
- pemetrexed: 500 mg/m2, intravenous, every 21 days x 4 cycles cisplatin: 75 mg/m2, intravenous, every 21 days x 4 cycles chemotherapy, surgery then chest radiation x 54 gray (Gy)
- id
- OG000
- title
- Pemetrexed
- param Type
- MEAN
- population Description
- All participants who had undergone surgery.
- reporting Status
- POSTED
- time Frame
- baseline to measured progressive disease
- title
- Time to Progressive Disease
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice